Macular degeneration trials in Poland

In Poland 12 Also abroad 218

12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Where
Bydgoszcz, Cracow, Tarnowskie Góry
Age
50 years and over
People
272 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07441642 · EU 2025-523704-77-00
Phase 3Taking people
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Where
Bielsko-Biala, Bydgoszcz, Cracow, Gliwice, Katowice, Lodz, Lublin, Olsztyn
Age
50 years and over
People
250 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06847542 · EU 2024-516924-32-00
Phase 3Taking people
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Where
Bydgoszcz, Cracow, Lodz, Olsztyn, Rzeszów, Tarnowskie Góry, Wroclaw
Age
50 years to 85 years
People
975 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06541704 · EU 2023-509547-27-00
Phase 2/3Taking people
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Where
Bydgoszcz, Warsaw
Age
60 years and over
People
274 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06635148 · EU 2022-500747-21-00
Phase 3Taking people
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Where
Bydgoszcz, Cracow, Lodz, Olsztyn, Rzeszów, Tarnowskie Góry, Warsaw
Age
50 years and over
People
304 worldwide
Run by
Amgen
See details and how to joinNCT07614776 · EU 2025-523500-72-00
Phase 2/3Taking people
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Where
Bydgoszcz, Gdansk, Katowice, Krakow, Olsztyn, Tarnowskie Góry
Age
50 years and over
People
960 worldwide
Run by
EyeBiotech Ltd.
See details and how to joinNCT07440225
Phase 2Enrolling by invitation
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Where
Bydgoszcz
Age
55 years and over
People
225 worldwide
Run by
Gyroscope Therapeutics Limited
See details and how to joinNCT05481827 · EU 2024-510946-15-00
Phase 2/3Not yet taking people in Poland
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
Where
Bydgoszcz, Cracow, Gdansk, Lodz, Lublin, Olsztyn, Warsaw
Age
65 years and over
People
125 worldwide
Run by
Shenzhen Oculgen Biomedical Technology Co. Ltd.
See details and how to join2026-526648-11-00 · EU 2026-526648-11-00
Phase 2Taking people
A Study in Adults With Geographic Atrophy
Where
Bielsko-Biala, Bydgoszcz, Cracow, Katowice, Olsztyn, Poznan, Walbrzych, Warsaw
Age
60 years and over
People
300 worldwide
Run by
Sitala Bio LTD
See details and how to joinNCT07606365 · EU 2026-525738-40-00
Phase 3Taking people
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
Where
Cracow, Lodz, Warsaw
Age
50 years to 120 years
People
210 worldwide
Run by
King's College Hospital NHS Trust
See details and how to joinNCT04663750 · EU 2023-504751-28-00
Phase 2Taking people
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Where
Bydgoszcz, Cracow, Gdansk, Lodz, Olsztyn
Age
55 years and over
People
324 worldwide
Run by
ONL Therapeutics
See details and how to joinNCT06659445 · EU 2024-513174-22-00
Phase 2/3Taking people
A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD)
Where
Bialystok, Bydgoszcz, Cracow, Gdansk, Katowice, Olsztyn, Tarnowskie Góry, Warsaw
Age
18 years and over
People
130 worldwide
Run by
Eyebiotech Limited
See details and how to join2025-524575-22-00 · EU 2025-524575-22-00